These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 9658744)
1. Cyfra 21-1 as a marker of lung cancer. Kinoshita M; Watanabe H; Ichiki M; Sumita S; Okubo Y; Matsunami M; Furuno H; Shiraishi T; Rikimaru T; Oizumi K Kurume Med J; 1998; 45(1):7-9. PubMed ID: 9658744 [TBL] [Abstract][Full Text] [Related]
2. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer. Lai RS; Hsu HK; Lu JY; Ger LP; Lai NS Chest; 1996 Apr; 109(4):995-1000. PubMed ID: 8635383 [TBL] [Abstract][Full Text] [Related]
3. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumour markers in bronchogenic carcinoma. Huang MS; Jong SB; Tsai MS; Lin MS; Chong IW; Lin HC; Hwang JJ Respir Med; 1997 Mar; 91(3):135-42. PubMed ID: 9135852 [TBL] [Abstract][Full Text] [Related]
4. Prognosis in bronchogenic squamous cell carcinoma groups divided according to serum squamous cell carcinoma-related antigen and cytokeratin 19 fragment levels. Kashiwabara K; Nakamura H; Esaki T Clin Chim Acta; 2000 Apr; 294(1-2):105-13. PubMed ID: 10727677 [TBL] [Abstract][Full Text] [Related]
5. Comparison of CYFRA 21-1 and squamous cell carcinoma antigen in detecting nasopharyngeal carcinoma. Lee JK; Hsieh JF; Tsai SC; Ho YJ; Sun SS; Kao CH Ann Otol Rhinol Laryngol; 2001 Aug; 110(8):775-8. PubMed ID: 11510737 [TBL] [Abstract][Full Text] [Related]
6. [Investigation of the usefulness of CYFRA 21-1 as a tumor marker in squamous cell carcinomas of the head and neck]. Sano K; Kataoka S; Katoh T; Kawauchi H; Morikawa S Nihon Jibiinkoka Gakkai Kaiho; 1997 Jul; 100(7):790-7. PubMed ID: 9277101 [TBL] [Abstract][Full Text] [Related]
7. The clinical value of Cyfra 21-1 estimation for lung cancer patients. Szturmowicz M; Sakowicz A; Rudzinski P; Zych J; Wiatr E; Zaleska J; Rowinska-Zakrzewska E Int J Biol Markers; 1996; 11(3):172-7. PubMed ID: 8915713 [TBL] [Abstract][Full Text] [Related]
8. High levels of cytokeratin 19 fragments but no evidence of cytokeratins 1, 2, 10/11, 14 or filaggrin in the serum of squamous cell lung carcinoma patients. Miédougé M; Devys A; Simon M; Rouzaud P; Salama G; Reyre J; Pujazon M; Carles P; Serre G Tumour Biol; 2001; 22(1):19-26. PubMed ID: 11054023 [TBL] [Abstract][Full Text] [Related]
9. Cyfra 21-1, a new marker of lung cancer. Grenier J; Pujol JL; Guilleux F; Daures JP; Pujol H; Michel FB Nucl Med Biol; 1994 Apr; 21(3):471-6. PubMed ID: 9296767 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of cytokeratin 19 fragment (CYFRA 21-1) as a tumor marker in malignant pleural effusion. Lai RS; Chen CC; Lee PC; Lu JY Jpn J Clin Oncol; 1999 Sep; 29(9):421-4. PubMed ID: 10563194 [TBL] [Abstract][Full Text] [Related]
11. Cytokeratin fragment 19 and squamous cell carcinoma antigen for early prediction of recurrence of squamous cell lung carcinoma. Sun SS; Hsieh JF; Tsai SC; Ho YJ; Lee JK; Kao CH Am J Clin Oncol; 2000 Jun; 23(3):241-3. PubMed ID: 10857885 [TBL] [Abstract][Full Text] [Related]
12. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and tissue polypeptide specific antigen (TPS) as tumour markers in lung cancer. Stieber P; Dienemann H; Hasholzner U; Müller C; Poley S; Hofmann K; Fateh-Moghadam A Eur J Clin Chem Clin Biochem; 1993 Oct; 31(10):689-94. PubMed ID: 7507359 [TBL] [Abstract][Full Text] [Related]
13. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer. Tas F; Aydiner A; Topuz E; Yasasever V; Karadeniz A; Saip P J Exp Clin Cancer Res; 2000 Dec; 19(4):477-81. PubMed ID: 11277326 [TBL] [Abstract][Full Text] [Related]
14. CYFRA 21-1: an indicator of survival and therapeutic effect in lung cancer. Takei Y; Minato K; Tsuchiya S; Takise A; Nakano H; Ezawa K; Fueki N; Hoshino H; Naruse I; Nomoto T; Makimoto T; Ishihara S; Saito R; Mori M Oncology; 1997; 54(1):43-7. PubMed ID: 8978592 [TBL] [Abstract][Full Text] [Related]
15. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA). Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221 [TBL] [Abstract][Full Text] [Related]
16. [The importance of the tumor marker CYFRA 21-1 in patients with lung cancer after surgery or chemotherapy]. Zissimopoulos A; Stellos K; Permenopoulou V; Petrakis G; Theodorakopoulos P; Baziotis N; Thalassinos N Hell J Nucl Med; 2007; 10(1):62-6. PubMed ID: 17450257 [TBL] [Abstract][Full Text] [Related]
17. Cytokeratin fragment 19 (CYFRA 21-1) and carcinoembryonic antigen for early prediction of recurrence of lung adenocarcinoma. Kao CH; Hsieh JF; Ho YJ; Ding HJ Lung; 1999; 177(5):333-7. PubMed ID: 10467024 [TBL] [Abstract][Full Text] [Related]
18. Serum CYFRA 21-1 in cervical cancer patients treated with radiation therapy. Suzuki Y; Nakano T; Ohno T; Abe A; Morita S; Tsujii H J Cancer Res Clin Oncol; 2000 Jun; 126(6):332-6. PubMed ID: 10870643 [TBL] [Abstract][Full Text] [Related]
19. Monitoring cytokeratin fragment 19 (CYFRA 21-1) serum levels for early prediction of recurrence of adenocarcinoma and squamous cell carcinoma in the lung after surgical resection. Yeh JJ; Liu FY; Hsu WH; Wang JJ; Ho ST; Kao A Lung; 2002; 180(5):273-9. PubMed ID: 12489021 [TBL] [Abstract][Full Text] [Related]
20. An evaluation of the tumour markers, carcinoembryonic antigen (CEA), cytokeratin marker (CYFRA 21-1) and neuron-specific enolase (NSE) in the differentiation of malignant from benign solitary pulmonary lesions. Seemann MD; Beinert T; Fürst H; Fink U Lung Cancer; 1999 Dec; 26(3):149-55. PubMed ID: 10598925 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]